Elsevier

Journal of Hepatology

Volume 73, Issue 1, July 2020, Pages 202-209
Journal of Hepatology

Special Section
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

https://doi.org/10.1016/j.jhep.2020.03.039Get rights and content

Summary

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.

Introduction

Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly named non-alcoholic fatty liver disease (NAFLD), affects about a quarter of the world's adult population, poses a major health and economic burden to all societies[1], [2], [3] and yet has no approved pharmacotherapy. The high prevalence of this disease has been fuelled by the rapid rise in levels of sedentary behaviour, low levels of physical activity, excess calorie intake relative to expenditure in nutritionally imbalanced and unhealthy diets.4 In parallel, the prevalence of poor metabolic health in adults from affluent countries is high, even in normal weight individuals.5,6 In this context of high risk and prevalence, the lack of clear nomenclature for liver disease not due to alcohol use disorder, alongside the absence of defined clinical criteria for a “positive” diagnosis of this disease, constitute urgent unmet needs in the field.

To tackle this challenge, an international panel of experts have detailed the rationale for an update of the nomenclature and metabolic dysfunction-associated fatty liver disease, MAFLD, has been proposed as a more appropriate term to describe the liver disease associated with known metabolic dysfunction.1,7 MAFLD, as with the previous term NAFLD, represents the hepatic manifestation of a multisystem disorder, which is heterogeneous in its underlying causes, presentation, course and outcomes.8 However, given its complex pathophysiology, it is unlikely that a single diagnostic test will become available so new diagnostic criteria will need to be developed to define MAFLD, as was the case for the metabolic syndrome, which notably has multiple definitions.5,[9], [10], [11], [12], [13], [14] Until now the exclusion of other chronic liver diseases, including “excess” alcohol intake, was necessary for the diagnosis of MAFLD. As the pathogenic process leading to MAFLD is now better understood and is seen to originate from an underlying state of systemic metabolic dysfunction, MAFLD is perceived as a standalone disease which warrants a positive diagnosis, rather than a “none”-disease rubric. Moreover, the rising prevalence of MAFLD makes its coexistence with other chronic liver diseases quite possible, further negating a diagnosis based on exclusion of concomitant diseases. It is therefore our belief that this disease needs to be defined by its own set of positive criteria, rather than by exclusion criteria.

Hence, in this work we propose a comprehensive, yet simple, set of criteria for the diagnosis of MAFLD that are independent of the amount of alcohol consumed and can be applied to patients in any clinical setting. We also bring clarity to the diagnostic criteria, which are distinct from inclusion criteria for research studies and clinical trials. The long-term impact will be to promote wider discussion, help clinicians in routine clinical care, allow comparison of different studies, assist regulatory agencies and other stakeholders in case definition for clinical trials, and facilitate documentation in the ICD systems and diagnosis-related groups. The inclusion and endpoints of clinical trials that have been the focus of multiple other initiatives will likely evolve as acceptance of the new nomenclature and definition progresses.15

Section snippets

Criteria for a diagnosis of MAFLD

Presently the definition of NAFLD as reported in most guidelines and recent publications is based on the presence of steatosis in >5% of hepatocytes in the absence of significant ongoing or recent alcohol consumption and other known causes of liver disease.[15], [16], [17], [18] Herein we propose a set of new “positive” criteria for the diagnosis of MAFLD regardless of alcohol consumption or other concomitant liver diseases.

Suggestion

MAFLD should be the single overarching term used to describe the disease. Disease severity would be best described by the grade of activity and the stage of fibrosis. This is similar to what is accepted for other chronic liver diseases and recognises that MAFLD activity grade is a continuum.35 This should replace the current dichotomous stratification into steatohepatitis and non-steatohepatitis which has limitations that are discussed below.

Rationale

There is no doubt that the transition from steatosis

Suggestion

We propose that patients with cirrhosis, with low or undetectable levels of steatosis, who meet the proposed diagnostic criteria for MAFLD should be considered under the umbrella of MAFLD, as MAFLD-related cirrhosis. The term “cryptogenic cirrhosis” in this group should be avoided.

The proposed diagnostic criteria for MAFLD-related cirrhosis are patients with cirrhosis in the absence of typical histological signs suggestive of steatohepatitis who meet at least one of the following criteria: past

Suggestion

Exclusion of alcohol-associated fatty liver disease (ALD) based on current criteria for alcohol use disorder,46 viral infections (HIV, HBV or HCV), drug-induced liver injury, autoimmune hepatitis either at baseline or at follow-up is not a prerequisite for diagnosis. Patients who meet the criteria to diagnose MAFLD as described above and who also have one of these concomitant conditions should be defined as having dual (or more) aetiology fatty liver disease47 (Box 3).

Rationale

With the dramatic rise in

Suggestion

We suggest that the terms “primary” and “secondary” hepatic steatosis are avoided because all pathological processes are secondary. Instead, we propose use of “alternative causes” of fatty liver disease to describe the latter that includes conditions such as: medications (corticosteroids, valproic acid, tamoxifen, methotrexate, and amiodarone), coeliac disease, starvation, total parenteral nutrition, severe surgical weight loss or disorders of lipid metabolism (abetalipoproteinemia,

The distinction between diagnostic criteria and inclusion criteria for clinical trials

Diagnostic criteria for clinical purposes in any disease or syndrome are distinct from inclusion criteria for clinical studies or trials, at least regarding their intended purpose (Table S1). Diagnostic criteria generally are a set of symptoms, signs and tests used in routine clinical care to broadly reflect the features of a disease. The aim is to identify individuals with the condition as accurately as possible, in order to guide their management. By contrast, inclusion criteria for trials or

Conclusion

In this consensus, an international panel of experts propose clear and simple criteria for a diagnosis of MAFLD that shifts it from a disease of exclusion to one of inclusion. The diagnosis is based on recognition of underlying abnormalities in metabolic health with acceptance that MAFLD may commonly coexist with other conditions (Fig. 1). We believe that the proposed diagnostic criteria are novel and practical. Future research will involve an iterative process of clinical validation of the

Financial support

ME and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206, APP1149976) and Project grants (APP1107178 and APP1108422). PNN is supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those

Authors' contributions

ME, PNM, SKS, QMS,GT, MRG, SZS, VWS, JFD, JS,TK, MA, LV, GS, CT, HYJ, JGF,HG, YY, HCP, CPO,PB, LA,MHZ,YF,WKC, NMS, SHA, LC, EB, VR, JG, contributed to conceptualisation and the writing of the manuscript.

Conflicts of interest

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying ICMJE disclosure forms for further details.

References (60)

  • S. McPherson et al.

    Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

    J Hepatol

    (2015)
  • R. Pais et al.

    A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

    J Hepatol

    (2013)
  • E. Vilar-Gomez et al.

    Fibrosis severity as a determinant of cause-specific mortality in patients with Advanced nonalcoholic fatty liver disease: a multi-national cohort study

    Gastroenterology

    (2018)
  • L.A. Adams et al.

    The natural history of nonalcoholic fatty liver disease: a population-based cohort study

    Gastroenterology

    (2005)
  • P.J. Thuluvath et al.

    Is cryptogenic cirrhosis different from NASH cirrhosis?

    J Hepatol

    (2018)
  • S. Caldwell et al.

    Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name…

    J Hepatol

    (2018)
  • Z. Younossi et al.

    The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options

    J Hepatol

    (2018)
  • M. Boyle et al.

    The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease

    J Hepatol

    (2018)
  • E.M. Brunt et al.

    Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease

    Mod Pathol

    (2003)
  • D.J. Chiang et al.

    The impact of obesity and metabolic syndrome on alcoholic liver disease

    Clin Liver Dis

    (2014)
  • M. Eslam et al.

    Genetics and epigenetics of NAFLD and NASH: clinical impact

    J Hepatol

    (2018)
  • A.L. Fracanzani et al.

    Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity

    Clin Gastroenterol Hepatol

    (2017)
  • M. Eslam et al.

    MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease

    Gastroenterology

    (2020 Feb 8)
  • Z. Younossi et al.

    Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

    Nat Rev Gastroenterol Hepatol

    (2018)
  • Y. Inoue et al.

    Epidemiology of obesity in adults: latest trends

    Curr Obes Rep

    (2018)
  • J. Araujo et al.

    Prevalence of optimal metabolic health in American adults: national health and nutrition examination survey 2009-2016

    Metab Syndr Relat Disord

    (2019)
  • J.I. Cleeman et al.

    Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)

    JAMA

    (2001)
  • H. Black et al.

    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

    JAMA

    (2003)
  • S.M. Grundy et al.

    Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement

    Circulation

    (2005)
  • K. Alberti et al.

    Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity

    Circulation

    (2009)
  • Cited by (0)

    Author names in bold designate shared co-first authorship

    Equal first authors.

    Equal senior authors.

    View full text